Product How it works Pricing Blog FAQ About Contact
Arbutus Biopharma

Arbutus Biopharma (NASDAQ: ABUS) revenue

Arbutus Biopharma reported revenue of $14.1m for fiscal 2025, 128.2% more than in fiscal 2024 ($6.2m). Since fiscal 2016 its revenue has grown by 844.5%, an average growth of 28.3% a year.

Arbutus Biopharma's best year of the last 10 was fiscal 2022. The biggest drop was in fiscal 2024, −66.0%.

Revenue, in millions of US dollars1.5201610.720175.920186.020196.9202011.0202139.0202218.120236.2202414.12025
Embed this chart

Copy this code into your website or blog. The chart updates with each new annual report.

Revenue by fiscal year

Fiscal yearRevenueChangeOperating profitOperating margin
2025$14.1m+128.2%−$38.2m−271.0%
2024$6.2m−66.0%−$76.3m−1,236.7%
2023$18.1m−53.5%−$78.1m−430.5%
2022$39.0m+255.1%−$65.5m−167.8%
2021$11.0m+58.9%−$73.5m−669.1%
2020$6.9m+15.0%−$57.8m−836.1%
2019$6.0m+1.1%−$143.9m−2,394.0%
2018$5.9m−44.4%−$89.8m−1,510.2%
2017$10.7m+617.6%−$110.9m−1,036.7%
2016$1.5m—−$491.6m−32,973.8%

The change compares each fiscal year with the one before. Operating margin is operating profit over revenue from the same filing. Figures are in millions of US dollars, except per-share amounts.

Arbutus Biopharma revenue compared with its sector

By revenue for its latest fiscal year, Arbutus Biopharma ranks 361st of the 422 US health care companies with a page on Celsmar. The sector median grew 11.7% in its latest fiscal year; Arbutus Biopharma, 128.2%.

RankCompanyRevenueRevenue growth
359thLineage Cell Therapeutics$14.6m53.2%
360thOpus Genetics$14.2m29.1%
361stArbutus Biopharma$14.1m128.2%
362ndHyperfine$13.6m5.2%
363rdTonix Pharmaceuticals$13.1m29.8%

Each amount is in the currency the company reports in; the rank converts them to US dollars at the 16 November 2026 exchange rate. The rest are in US health care stocks.

Questions about the revenue of Arbutus Biopharma

How much revenue did Arbutus Biopharma make in fiscal 2025?
Arbutus Biopharma reported revenue of $14.1m for fiscal 2025, compared with $6.2m in fiscal 2024.
How much has the revenue of Arbutus Biopharma grown?
Between fiscal 2016 and fiscal 2025 it went from $1.5m to $14.1m: 844.5% more, an average growth of 28.3% a year.
What was the best year for revenue at Arbutus Biopharma?
Of its last 10 fiscal years, fiscal 2022, with $39.0m.
Where does Arbutus Biopharma rank in its sector by revenue?
It ranks 361st of the 422 US health care companies with a page on Celsmar, by revenue for its latest fiscal year.
Where do the figures for Arbutus Biopharma come from?
From the annual report (Form 10-K) that Arbutus Biopharma files with the SEC, the US securities regulator. Each fiscal year links to its filing.

Where each figure comes from

From the annual report (Form 10-K) that Arbutus Biopharma files with the SEC. The filing for each fiscal year: 2025 · 2024 · 2023 · 2022 · 2021 · 2020 · 2019 · 2018 · 2017 · 2016. More on Arbutus Biopharma: the Arbutus Biopharma page · annual accounts · net income · insider transactions.

Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.